Kai Pharms Inc Drug Patent Portfolio
Kai Pharms Inc owns 1 orange book drug protected by 8 US patents Given below is the list of Kai Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10344765 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US11162500 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US9820938 | Stable liquid formulation of AMG 416 (etelcalcetide) | 27 Jun, 2034 | Active |
| US8999932 | Therapeutic agents for reducing parathyroid hormone levels | 07 Feb, 2031 | Active |
| US8377880 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
| US9278995 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
| US9701712 | Therapeutic agents for reducing parathyroid hormone levels | 29 Jul, 2030 | Active |
Latest Legal Activities on Kai Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kai Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Aug, 2023 | US9278995 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2022 | US10344765 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2022 | US8999932 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Nov, 2021 | US11162500 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Nov, 2021 | US11162500 |
|
Email Notification
Critical
| 14 Oct, 2021 | US11162500 |
|
Issue Notification Mailed
Critical
| 13 Oct, 2021 | US11162500 |
|
Application Is Considered Ready for Issue
Critical
| 04 Oct, 2021 | US11162500 |
| Dispatch to FDC | 04 Oct, 2021 | US11162500 |
|
Issue Fee Payment Received
Critical
| 02 Aug, 2021 | US11162500 |
|
Issue Fee Payment Verified
Critical
| 02 Aug, 2021 | US11162500 |
|
Email Notification
Critical
| 19 Jul, 2021 | US11162500 |
|
Electronic Review
Critical
| 19 Jul, 2021 | US11162500 |
|
Mail Notice of Allowance
Critical
| 19 Jul, 2021 | US11162500 |
|
Notice of Allowance Data Verification Completed
Critical
| 14 Jul, 2021 | US11162500 |
Kai Pharms Inc Drug Patents' Oppositions Filed in EPO
Kai Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 19, 2018, by Hexal Ag. This opposition was filed on patent number EP14742093A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17160312A | Dec, 2021 | Adalvo Ltd. | Granted and Under Opposition |
| EP17160312A | Dec, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17160312A | Dec, 2021 | Synthon BV | Granted and Under Opposition |
| EP17160312A | Dec, 2021 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP14742093A | Jan, 2018 | Hexal AG | Opposition rejected |
Kai Pharms Inc's Family Patents
Kai Pharms Inc Drug List
Given below is the complete list of Kai Pharms Inc's drugs and the patents protecting them.
1. Parsabiv
Parsabiv is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10344765 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US11162500 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US11959486 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US9820938 | Stable liquid formulation of AMG 416 (etelcalcetide) |
27 Jun, 2034
(9 years from now)
| Active |
| US8999932 | Therapeutic agents for reducing parathyroid hormone levels |
07 Feb, 2031
(6 years from now)
| Active |
| US8377880 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
| US9278995 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
| US9701712 | Therapeutic agents for reducing parathyroid hormone levels |
29 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Parsabiv's drug page